Introduction
In the last decade, members of the genus Candida have emerged as major opportunistic pathogens, mainly due to the increase in the immunocompromised patient population [1, 2] . While C. albicans had been the dominant species recovered from such individuals, the profi le of etiologic agents causing invasive candidiasis has changed with an
Materials and methods

Yeast isolates and identifi cation
In a retrospective study, fi les of patients hospitalized in various departments of Sfax University Hospital were selected on the basis of the recovery of C. glabrata from blood samples or sterile sites. Sixty-fi ve C. glabrata clinical isolates were collected from 46 patients from January 2001 to December 2007. Fifty of the 65 strains were isolated from blood or systemic sites (44 blood cultures and 6 deep-site specimens) and 15 from peripheral samples obtained from 13 patients (Table 2 ). Data about risk factors and previous azole therapy were collected. Two reference strains ATCC 2001 and CBS138 were included as controls in the present investigations. To identify the isolates they were inoculated onto Candiselect ID medium (Bio-Rad, France) and incubated at 37 ° C for 48 h. C. glabrata was initially identifi ed by the green color of its colonies, which was subsequently confi rmed by ID32C (Biom é rieux, France) assimilation test and Glabrata RTT (Fumouze, Diagnostic, Paris France).
DNA extraction
Genomic DNA was prepared from cell pellets obtained from 5 ml of fresh overnight culture in yeast peptone glucose (YPG) medium. Cells were digested with yeast lytic enzyme followed by SDS-proteinase K and the DNA was extracted with phenol-chloroform, and precipitated with ethanol as described previously [6] .
Susceptibility testing
Susceptibility to fl uconazole was determined by measuring the minimum inhibitory concentration (MIC) obtained through the use of the E-test (AB BIODISK, Solna, Sweden). In this assay, one colony from a fresh culture on yeast extract peptone dextrose (YEPD) agar plates was suspended in 2 ml of 0.85M NaCl to match a 0.5 McFarland standard. The inoculum was swabbed into RPMI 1640 agar plates (AES laboratories, Cambourg France) and allowed to dry for 15 min before E-test strips were applied. Plates were incubated at 37 ° C and the minimum inhibitory concentration (MIC) was read after 24 h and 48 h as the drug concentration at which the inhibition ellipse intercepted the scale on the antifungal strips.
Typing yeast isolates
Molecular typing of invasive C. glabrata isolates was performed as previously described [7] by multiplex PCR using three microsatellite markers RPM2, ERG3 and MTI. Amplifi cation was carried in 20 μ l volume containing 2 μ l of C. glabrata DNA, 1X STR * buffer (Promega, USA), 0.2 mM deoxynucleoside triphosphate, 5 pmol each of the RPM2 and ERG3 primers, 20 pmol each of the MTI primers and 1.25U of Ampli Taq Gold DNA polymerase (Applied Biosystems, Courtaboeuf, France). After an initial step of 10 min at 95 ° C, the PCR included 30 cycles of 95 ° C for 30 s, 55 ° C for 30 s and 72 ° C for 1 min, followed by an additional step of 5 min at 72 ° C. One microliter of the PCR mixture was then added to 24 μ l of formamide containing 0.5 μ l of Genescan LIZ 500 marker (Applied Biosystems, Courtaboeuf, France) and denaturated for 2 min at 95 ° C. The PCR products were subjected to electrophoresis on an ABI 310 sequence analyzer and the data were analyzed with the Genescan software (Applied Biosystems, France).
Sequence analysis
To verify that the differences observed between the different alleles were due to the number of microsatellite sequence repeats, one allele of each marker was sequenced after ampli fi cation using unlabeled primers. The PCR products were puri fi ed using the Mini Elute puri fi cation kit (Qiagen, France) and submitted to bidirectional cycle sequencing with the Big Dye terminator V3.0 reaction kit. The sequencing reaction mixtures were analyzed by using an ABI 310 sequence analyzer with the Sequence Analysis software (Applied Biosystems, France).
Statistical analysis
The index of discrimination was calculated by the following formula [8] .
where N is the number of isolates, x is the number of groups and yi is the number of isolates falling into i group. An UPGMA method was employed for the phylogenetic analysis (http://pubmlst.org) and correlation analyses (Spearman ' s Rho) were done using SPSS (Version 14.0).
Results
From January 2001 to December 2007 we collected 234
Candida isolates from blood samples and sterile sites, including 50 (21.4%) C. glabrata strains. Invasive isolates were tested for susceptibility to fl uconazole. Twenty eight (58%) were sensitive, 16 (33%) were dose-dependent sensitive, and only fi ve (8.3%) isolates were resistant to fl uconazole. patients 5 and 7, respectively. For each patient, one of the two isolates was identical to the one isolated from the colonizing sites. The second isolate of patient 5 was different and showed a lower susceptibility to fl uconazole (Table 2 ). This patient had been started on antifungal therapy with fl uconazole (400 mg/day) 2 days prior to the diagnosis of invasive infection. In addition, we found a deletion of 10 bp in the RPM2 marker in a second invasive isolate (patient 14). There was no signifi cant association ( P Ͼ 0.05) of genotype with in vitro susceptibility profi les to fl uconazole, hospitalization unit or date of isolation. However, we found three different clusters, each of them representing identical isolates, and all were recovered in 2006 in the intensive care units (ICU) of the Department of Neonatology (Fig. 2) .
Discussion
The prevalence of systemic C. glabrata infections has increased during the last few years [9] . In our institution, they accounted for 21.4% of candidemia cases during the period of the study. An equivalent incidence was found in the USA [3] but less elevated rates were found in France 9% [10] and in a multicenter surveillance study in Europe 12 -14% [11] . A relatively low level of resistance to fl uconazole (8.3%) was found for all isolates tested in this investigation. The rate of resistance to fl uconazole in other countries was variable, i.e., from 10.6% in Asia-pacifi c [12], 16.5% in Europe and 18% in North America [12] .
Several investigators assumed that several factors were responsible for the increase in the number of Candida glabrata isolates found to have higher MICs to fl uconazole, such as previous antibiotherapy [13 -15] and prophylaxis by fl uconazole [16 -18] . Ngynen et al . reported that 13% of patients with candidemia had received systemic antifungal agents [13] . In our study, the majority of patients had been treated with antibiotherapy before they developed candidiasis, but no patient received fl uconazole prophylaxis. The high susceptibility to fl uconazole is probably the result of rare fl uconazole prophylaxis during the study period as also suggested by some authors [19, 20] . The high prevalence of C. glabrata could be due to a complex set of factors, including demographic changes, increased number of immunocompromised patients, or changes in the ecology of the C andida fl ora rather than the selection of C. glabrata due to drug pressure [21, 22] .
The typing of unrelated isolates generated a less discriminatory power than that found by Foulet et al . (D ϭ 0.84 for 138 unapparent isolates), probably due to the relatively limited number of isolates [7] .
Eleven of 13 patients (84%) were infected by isolates initially found to be colonizing these individuals. These Invasive isolates were collected from 23 women and 23 men, with a mean age of 43 years. The most common risk factors associated with invasive infection were prior antibiotherapy (92%), use of central intravenous catheters (43%), previous colonization (28%), parenteral nutrition and diabetes (20%), and previous chemotherapy (13%), but none of the patients had received azole prophylaxis.
The typing of isolates by three microsatellite markers generated twelve distinct multilocus genotypes. We found four alleles for RPM2 loci, six alleles for MTI and seven for ERG3. Irregular distribution of genotypes among isolates was observed with a predominance of multilocus genotype (G1) in 38% of the isolates. The second (G11) and third (G9) most frequent genotypes represent 16% and 14% of the strains, respectively (Table 1) . Phylogenetic analysis revealed haplotype distribution among unrelated isolates as shown in Fig. 1 . Discriminatory power was estimated between them and was equal to (D ϭ 0.811).
In order to detect genotypic and phenotypic variation of C. glabrata isolates within the same patient, isolates from blood cultures and other body sites were genotyped and tested for susceptibility (Table 2) . Isolates collected from blood samples or sterile sites and diverse anatomical sites showed the same genotype in 11 patients. The genotype was different in two patients (nos. 8 and 11).
The in vitro susceptibility profi le of colonizing and infectious isolates to fl uconazole was similar in nine patients. A change of the profi le was detected for two patients. Patient 9 was treated by fl uconazole, which was replaced by amphotericin B due to the development of resistance. One month later, we identifi ed an isolate of the same genotype which was found to be sensitive to fl uconazole. We obtained a resistant isolate from patient 4 who was treated with a 4 g cumulative dose of fl uconazole (Table 2) . Two morphologically different C. glabrata isolates were simultaneously obtained from the same deep site localization (blood specimens and pulmonary abscess) of results, despite the low number, have been reported for C . albicans , invasive isolates which were also shown to be identical to colonizing strains in 70 -90% of cases [23] . In almost all reported cases, there were no variations in susceptibility to fl uconazole between isolates recovered from blood and colonizing sites. Safdar et al ., who reported similar results, observed no differences in fl uconazole susceptibility or in genotype profi les among C. glabrata isolates associated with either haematogenous dissemination or colonization [24] . For one patient who had undergone prolonged treatment with fl uconazole, we were able to isolate a more resistant strain. The hypothesis that fl uconazole contributes to the emergence of more resistant C. glabrata isolates has been suggested by some authors [16 -18] . Moreover, a selection of a new isolate with higher MIC has been observed and the hypothesis of selection pressure after fl uconazole therapy has also been discussed.
We also showed minor changes (a deletion of 10 pb) in the isolate ' s genotype of patient 14 that could represent microevolution as reported by Metzgar et al . These authors suggested changes in microsatellite sequences in C. albicans that had been isolated before and after treatment with different doses of fl uconazole [25] . However, our patient was not under antifungal azole therapy. We concluded that the haploid nature of the genome allows it to mutate rapidly and this modifi cation can involve a change of its sensitivity profi le to fl uconazole in the absence of antifungal therapy as has been suggested by Shin et al . [26] . Mutation rates in microsatellite sequences were estimated in yeasts. Instability of CAG and CTG trinucleotide repeats in Saccharomyces cerevisiae , which is closely related to C. glabrata , varied from 4 ϫ 10 -4 to 18 ϫ 10 -4 [27, 28] .
In our cases, we did not fi nd an association between a particular genotype and susceptibility to fl uconazole ( P Ͼ 0.05) as previously noted by some authors [29, 30] . Four resistant isolates fell into two different multilocus genotypes (G2 and G9) which were distant in the dendrogram. Dodgson et al ., by multilocus sequence typing (MLST), also did not fi nd a correlation between fl uconazole resistance and genotypes and that resistant isolates were classifi ed into six different ST types [30] .
In our hospital, more than one third of the C. glabrata isolates had the same genotype (G1 ϭ 38%). This suggests, as reported by de Meeus et al . [29] , that nosocomial infections or frequent interpatient transfers, may be important factors in the transmission of C. glabrata. Furthermore, cluster 3 (G9) represents a less common genotype and the isolates were collected in the same department, at the same period (less than two months) suggesting a cross transmission between patients. For this reason, preventive measures should be amplifi ed to minimize the risk of such infections. In summary, the predominance of some genotypes could be explained by nosocomial transmission or a selective ecological advantage rather than an emergence of a resistant isolate.
